Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: Results from the action in diabetes and vascular disease: Preterax and diamicron controlled evaluation (ADVANCE) trial

John Chalmers, Hisatomi Arima, Mark Woodward, Giuseppe Mancia, Neil Poulter, Yoichiro Hirakawa, Sophia Zoungas, Anushka Patel, Bryan Williams, Stephen Harrap

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%-43%) among patients with CCB at baseline compared with 5% (-12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%-25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (-8% to 28%) versus 6% (-10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalHypertension
Volume63
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

perindopril drug combination indapamide
Indapamide
Gliclazide
Perindopril
Calcium Channel Blockers
Vascular Diseases
Type 2 Diabetes Mellitus
Mortality

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus : Results from the action in diabetes and vascular disease: Preterax and diamicron controlled evaluation (ADVANCE) trial. / Chalmers, John; Arima, Hisatomi; Woodward, Mark; Mancia, Giuseppe; Poulter, Neil; Hirakawa, Yoichiro; Zoungas, Sophia; Patel, Anushka; Williams, Bryan; Harrap, Stephen.

In: Hypertension, Vol. 63, No. 2, 02.2014, p. 259-264.

Research output: Contribution to journalArticle

Chalmers, John ; Arima, Hisatomi ; Woodward, Mark ; Mancia, Giuseppe ; Poulter, Neil ; Hirakawa, Yoichiro ; Zoungas, Sophia ; Patel, Anushka ; Williams, Bryan ; Harrap, Stephen. / Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus : Results from the action in diabetes and vascular disease: Preterax and diamicron controlled evaluation (ADVANCE) trial. In: Hypertension. 2014 ; Vol. 63, No. 2. pp. 259-264.
@article{356cdcac0e004ee68eef550a8ece5968,
title = "Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus: Results from the action in diabetes and vascular disease: Preterax and diamicron controlled evaluation (ADVANCE) trial",
abstract = "The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28{\%} (95{\%} confidence interval, 10{\%}-43{\%}) among patients with CCB at baseline compared with 5{\%} (-12{\%} to 20{\%}) among those without CCB (P homogeneity=0.02) and 14{\%} (2{\%}-25{\%}) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12{\%} (-8{\%} to 28{\%}) versus 6{\%} (-10{\%} to 19{\%}) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.",
author = "John Chalmers and Hisatomi Arima and Mark Woodward and Giuseppe Mancia and Neil Poulter and Yoichiro Hirakawa and Sophia Zoungas and Anushka Patel and Bryan Williams and Stephen Harrap",
year = "2014",
month = "2",
doi = "10.1161/HYPERTENSIONAHA.113.02252",
language = "English",
volume = "63",
pages = "259--264",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Effects of combination of perindopril, indapamide, and calcium channel blockers in patients with type 2 diabetes mellitus

T2 - Results from the action in diabetes and vascular disease: Preterax and diamicron controlled evaluation (ADVANCE) trial

AU - Chalmers, John

AU - Arima, Hisatomi

AU - Woodward, Mark

AU - Mancia, Giuseppe

AU - Poulter, Neil

AU - Hirakawa, Yoichiro

AU - Zoungas, Sophia

AU - Patel, Anushka

AU - Williams, Bryan

AU - Harrap, Stephen

PY - 2014/2

Y1 - 2014/2

N2 - The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%-43%) among patients with CCB at baseline compared with 5% (-12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%-25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (-8% to 28%) versus 6% (-10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.

AB - The objective of the present analysis was to determine the effects of a fixed combination of perindopril and indapamide in combination with calcium channel blockers (CCBs) in patients with type 2 diabetes mellitus. The Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) trial was a factorial randomized controlled trial. A total of 11 140 patients with type 2 diabetes mellitus were randomly assigned to fixed combination of perindopril-indapamide (4/1.25 mg) or placebo. Effects of randomized treatment on mortality and major cardiovascular outcomes were examined in subgroups defined by baseline use of CCBs. Patients on CCB at baseline (n=3427) constituted a higher risk group compared with those not on CCB (n=7713), with more extensive use of antihypertensive and other protective therapies. Active treatment reduced the relative risk of death by 28% (95% confidence interval, 10%-43%) among patients with CCB at baseline compared with 5% (-12% to 20%) among those without CCB (P homogeneity=0.02) and 14% (2%-25%) for the whole population. Similarly, the relative risk reduction for major cardiovascular events was 12% (-8% to 28%) versus 6% (-10% to 19%) for those with and without CCB at baseline although the difference was not statistically significant (P homogeneity=0.38). There was no detectable increase in adverse effects in those receiving CCB. The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.

UR - http://www.scopus.com/inward/record.url?scp=84892923676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892923676&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.113.02252

DO - 10.1161/HYPERTENSIONAHA.113.02252

M3 - Article

C2 - 24324048

AN - SCOPUS:84892923676

VL - 63

SP - 259

EP - 264

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 2

ER -